- Home
- AGEN
AGEN
Agenus Inc.
as 06-30-2025 1:30pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 87.7M | IPO Year: | 2000 |
| Target Price: | $13.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $18.74 | Next Earning Date: | 08-07-2025 |
| Revenue: | $99,524,000 | Revenue Growth: | -38.34% |
| Revenue Growth (this year): | 12.69% | Revenue Growth (next year): | -3.18% |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Zacks
7 days ago
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
Zacks
12 days ago
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
MT Newswires
14 days ago
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo
Business Wire
14 days ago
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
Insider Monkey
15 days ago
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock
Zacks
15 days ago
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
Business Wire
21 days ago
Agenus Announces Virtual Annual Shareholders Meeting
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.